Patents by Inventor Christine Rothe
Christine Rothe has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Publication number: 20180030101Abstract: The present disclosure provides hNGAL muteins that bind a pyoverdine family member or pyochelin and can be used in various application including pharmaceutical applications, for example, to inhibit or reduce growth of P. aeruginosa. The present disclosure also concerns methods of making one or more pyoverdine- or pyochelin-binding muteins described herein as well as compositions comprising one or more of such muteins. The present disclosure further relates to nucleic acid molecules encoding such muteins and to methods for generation of such muteins and nucleic acid molecules. In addition, the application discloses therapeutic and/or diagnostic uses of these muteins as well as compositions comprising one or more of such muteins.Type: ApplicationFiled: October 6, 2017Publication date: February 1, 2018Inventors: Carsten CORVEY, Heike STUMP, Jochen KRUIP, Bernhard CALANDRA, Astrid REY, Nathalie KARST, Michael MOUREZ, Laurent FRAISSE, Christine ROTHE, Andrea ALLERSDORFER, Alexander WIEDENMANN, Marlon HINNER, Bradley LUNDE, Kristian JENSEN, Martin HÜLSMEYER
-
Publication number: 20180016312Abstract: The present disclosure provides hNGAL muteins that bind Ang-2 and can be used in various application including pharmaceutical applications, for example, to inhibit or reduce angiogenesis. The present disclosure also concerns methods of making one or more muteins described herein as well as compositions and combinations comprising one or more of such muteins. The present disclosure further relates to nucleic acid molecules encoding such muteins and to methods for generation of such muteins and nucleic acid molecules. In addition, the application discloses therapeutic and/or diagnostic uses of these muteins as well as compositions and combinations comprising one or more of such muteins.Type: ApplicationFiled: January 27, 2016Publication date: January 18, 2018Applicant: Pieris Pharmaceuticals GmbHInventors: Rachida Siham BEL AIBA, Andrea ALLERSDORFER, Alexander WIEDENMANN, Christine ROTHE, Shane OLWILL, Hendrik GILLE, Laurent Audoly
-
Publication number: 20170267734Abstract: The present disclosure provides hNGAL muteins that bind a pyoverdine family member or pyochelin and can be used in various application including pharmaceutical applications, for example, to inhibit or reduce growth of P. aeruginosa. The present disclosure also concerns methods of making one or more pyoverdine- or pyochelin-binding muteins described herein as well as compositions comprising one or more of such muteins. The present disclosure further relates to nucleic acid molecules encoding such muteins and to methods for generation of such muteins and nucleic acid molecules. In addition, the application discloses therapeutic and/or diagnostic uses of these muteins as well as compositions comprising one or more of such muteins.Type: ApplicationFiled: May 23, 2017Publication date: September 21, 2017Inventors: Carsten CORVEY, Heike STUMP, Jochen KRUIP, Bernhard CALANDRA, Astrid REY, Nathalie KARST, Michael MOUREZ, Laurent FRAISSE, Christine ROTHE, Andrea ALLERSDORFER, Alexander WIEDENMANN, Marlon HINNER, Bradley LUNDE, Kristian JENSEN, Martin HÜLSMEYER
-
Publication number: 20170173112Abstract: The present disclosure relates to novel lipocalin muteins which bind to PCSK9. The disclosure also provides corresponding nucleic acid molecules encoding lipocalin muteins and methods for producing lipocalin muteins as well as their encoding nucleic acid molecules.Type: ApplicationFiled: February 28, 2017Publication date: June 22, 2017Applicant: Daiichi Sankyo Co., Ltd.Inventors: Gabriele MATSCHINER, Christine ROTHE, Andreas HOHLBAUM, Andrea ALLERSDORFER, Rachida Siham Bel AIBA, Marlon HINNER, Alexander WIEDENMANN, Bradley LUNDE, Shinji YAMAGUCHI, Takahide ABURATANI, Ryuji HASHIMOTO, Tohru TAKAHASHI, Chikako NAGASAKI, Futoshi NARA, Tomohiro NISHIZAWA
-
Publication number: 20170166615Abstract: The present disclosure provides hNGAL muteins that bind CGRP and can be used in various application including pharmaceutical applications, for example, migraine. The present disclosure also concerns methods of making one or more muteins described herein as well as compositions and combinations comprising one or more of such muteins. The present disclosure further relates to nucleic acid molecules encoding such muteins and to methods for generation of such muteins and nucleic acid molecules.Type: ApplicationFiled: December 7, 2016Publication date: June 15, 2017Applicant: Daiichi Sankyo Co., Ltd.Inventors: GABRIELE MATSCHINER, Christine ROTHE, Alexander WIEDENMANN, Rachida Siham BEL AIBA, Marlon HINNER, Andrea ALLERSDORFER, Bradley LUNDE, Kazufumi KUBOTA, Mitsuhiro MAKINO, Sakiko TAKAHASHI, Ryuji HASHIMOTO, Tohru TAKAHASHI, Mamoru OTOYO
-
Patent number: 9598476Abstract: The present disclosure relates to novel lipocalin muteins which bind to PCSK9. The disclosure also provides corresponding nucleic acid molecules encoding lipocalin muteins and methods for producing lipocalin muteins as well as their encoding nucleic acid molecules.Type: GrantFiled: August 28, 2015Date of Patent: March 21, 2017Assignee: Daiichi Sankyo Co., Ltd.Inventors: Gabriele Matschiner, Christine Rothe, Andreas Hohlbaum, Andrea Allersdorfer, Rachida Siham Bel Aiba, Marlon Hinner, Alexander Wiedenmann, Bradley Lunde, Shinji Yamaguchi, Takahide Aburatani, Ryuji Hashimoto, Tohru Takahashi, Chikako Nagasaki, Futoshi Nara, Tomohiro Nishizawa
-
Publication number: 20170029477Abstract: The present invention relates to fusion molecules that have binding specificity for pyoverdine type I, II and III and pyochelin and can be used in various applications, including diagnostic and/or therapeutic applications, for example, to inhibit or reduce growth of P. aeruginosa and/or to prevent or treat P. aeruginosa biofilm infection as well as diseases or disorders associated with P. aeruginosa biofilm infection. The present invention also concerns methods of producing the fusion molecules described herein as well as compositions and kits comprising such fusion molecules. The present invention further relates to nucleic acid molecules encoding the fusion molecules described herein.Type: ApplicationFiled: July 6, 2016Publication date: February 2, 2017Inventors: Carsten Corvey, Heike Stump, Jochen Kruip, Christian Lange, Ingo Focken, Dorothea Rat, Thomas Stuedemann, Hans-Falk Rasser, Juergen Schaefer, Bernard Calandra, Astrid Rey, Michael Mourez, Laurent Fraisse, Christine Rothe, Andrea Allersdorfer, Alexander Wiedenmann, Marlon Hinner, Bradley Lunde, Kristian Jensen, Martin Hülsmeyer
-
Publication number: 20160024161Abstract: The present disclosure relates to novel lipocalin muteins which bind to PCSK9. The disclosure also provides corresponding nucleic acid molecules encoding lipocalin muteins and methods for producing lipocalin muteins as well as their encoding nucleic acid molecules.Type: ApplicationFiled: August 28, 2015Publication date: January 28, 2016Applicant: Daiichi Sankyo Co., Ltd.Inventors: Gabriele MATSCHINER, Christine Rothe, Andreas Hohlbaum, Andrea Allersdorfer, Rachida Siham Bel Aiba, Marlon Hinner, Alexander Wiedenmann, Bradley Lunde, Shinji Yamaguchi, Takahide Aburatani, Ryuji Hashimoto, Tohru Takahashi, Chikako Nagasaki, Futoshi Nara, Tomohiro Nishizawa
-
Patent number: 9150629Abstract: The present disclosure relates to novel lipocalin muteins which bind to PCSK9. The disclosure also provides corresponding nucleic acid molecules encoding lipocalin muteins and methods for producing lipocalin muteins as well as their encoding nucleic acid molecules.Type: GrantFiled: March 13, 2014Date of Patent: October 6, 2015Assignee: DAIICHI SANKYO CO., LTD.Inventors: Gabriele Matschiner, Christine Rothe, Andreas Hohlbaum, Andrea Allersdorfer, Rachida Siham Bel Aiba, Marlon Hinner, Alexander Wiedenmann, Bradley Lunde, Shinji Yamaguchi, Takahide Aburatani, Ryuji Hashimoto, Tohru Takahashi, Chikako Nagasaki, Futoshi Nara, Tomohiro Nishizawa
-
Publication number: 20140288008Abstract: The present disclosure relates to novel lipocalin muteins which bind to PCSK9. The disclosure also provides corresponding nucleic acid molecules encoding lipocalin muteins and methods for producing lipocalin muteins as well as their encoding nucleic acid molecules.Type: ApplicationFiled: March 13, 2014Publication date: September 25, 2014Applicants: Daiichi Sankyo Company, Limited, Pieris AGInventors: GABRIELE MATSCHINER, CHRISTINE ROTHE, ANDREAS HOHLBAUM, ANDREA ALLERSDORFER, RACHIDA SIHAM BEL AIBA, MARLON HINNER, ALEXANDER WIEDENMANN, SHINJI YAMAGUCHI, TAKAHIDE ABURATANI, RYUJI HASHIMOTO, TOHRU TAKAHASHI, CHIKAKO NAGASAKI, FUTOSHI NARA, TOMOHIRO NISHIZAWA
-
Patent number: 8329886Abstract: The present invention relates to antibody molecules capable of specifically recognizing two regions of the ?-A4 peptide, wherein the first region comprises the amino acid sequence AEFRHDSGY as shown in SEQ ID NO: 1 or a fragment thereof and wherein the second region comprises the amino acid sequence VHHQKLVFFAEDVG as shown in SEQ ID NO: 2 or a fragment thereof. Furthermore, nucleic acid molecules encoding the inventive antibody molecules and vectors and hosts comprising said nucleic acid molecules are disclosed. In addition, the present invention provides for compositions, preferably pharmaceutical or diagnostic compositions, comprising the compounds of the invention as well as for specific uses of the antibody molecules, nucleic acid molecules, vectors or hosts of the invention.Type: GrantFiled: May 16, 2012Date of Patent: December 11, 2012Assignees: Hoffman-La Roche Inc., Morphosys AGInventors: Michael Bardroff, Bernd Bohrmann, Manfred Brockhaus, Walter Huber, Titus Kretzschmar, Hansruedi Loetscher, Corinna Löhning, Christer Nordstedt, Christine Rothe
-
Patent number: 8273688Abstract: The present invention is directed to the preparation and use of a collection of antibody heavy chain complementarity determining region 3 (HCDR3) members, where diversity of the collection is a function of the length of the HCDR3 members. The diversity of the collection of HCDR3 regions substantially represents the natural amino acid distribution of HCDR3 in the human repertoire. This natural amino acid distribution can be represented by biasing the complete random distribution of amino acids, accordingly, in the HCDR3 encoding DNA sequence by using trinucleotide mutagenesis (TRIM) technology. A collection of HCDR3 members of the invention each can be comprised within a variable region of an antibody (or fragment thereof) to form a library of synthetic antibodies or antibody fragments. The invention also provides nucleic acid molecules encoding such diverse collection and methods of making and using the same.Type: GrantFiled: December 15, 2006Date of Patent: September 25, 2012Assignee: MorphoSys AGInventors: Markus Enzelberger, Stefanie Thiel, Josef Prassler, Stefanie Urlinger, Christine Rothe
-
Publication number: 20120225478Abstract: The present invention relates to antibody molecules capable of specifically recognizing two regions of the ?-A4 peptide, wherein the first region comprises the amino acid sequence AEFRHDSGY as shown in SEQ ID NO: 1 or a fragment thereof and wherein the second region comprises the amino acid sequence VHHQKLVFFAEDVG as shown in SEQ ID NO: 2 or a fragment thereof. Furthermore, nucleic acid molecules encoding the inventive antibody molecules and vectors and hosts comprising said nucleic acid molecules are disclosed. In addition, the present invention provides for compositions, preferably pharmaceutical or diagnostic compositions, comprising the compounds of the invention as well as for specific uses of the antibody molecules, nucleic acid molecules, vectors or hosts of the invention.Type: ApplicationFiled: May 16, 2012Publication date: September 6, 2012Inventors: Michael Bardroff, Bernd Bohrmann, Manfred Brockhaus, Walter Huber, Titus Kretzschmar, Hansruedi Loetscher, Corinna Löhning, Christer Nordstedt, Christine Rothe
-
Patent number: 8216577Abstract: The present invention relates to antibody molecules capable of specifically recognizing two regions of the ?-A4 peptide, wherein the first region comprises the amino acid sequence AEFRHDSGY as shown in SEQ ID NO: 1 or a fragment thereof and wherein the second region comprises the amino acid sequence VHHQKLVFFAEDVG as shown in SEQ ID NO: 2 or a fragment thereof. Furthermore, nucleic acid molecules encoding the inventive antibody molecules and vectors and hosts comprising said nucleic acid molecules are disclosed. In addition, the present invention provides for compositions, preferably pharmaceutical or diagnostic compositions, comprising the compounds of the invention as well as for specific uses of the antibody molecules, nucleic acid molecules, vectors or hosts of the invention.Type: GrantFiled: July 28, 2009Date of Patent: July 10, 2012Assignees: F. Hoffmann-La Roche AG, MorphoSys AGInventors: Michael Bardroff, Bernd Bohrmann, Manfred Brockhaus, Walter Huber, Titus Kretzschmar, Hansruedi Loetscher, Corinna Löhning, Christer Nordstedt, Christine Rothe
-
Patent number: 7794719Abstract: The present invention relates to antibody molecules capable of specifically recognizing two regions of the R-A4 peptide, wherein the first region comprises the amino acid sequence AEFRHDSGY as shown in SEQ ID NO: 1 or a fragment thereof and wherein the second region comprises the amino acid sequence VHHQKLVFFAEDVG as shown in SEQ ID NO: 2 or a fragment thereof. Furthermore, nucleic acid molecules encoding the inventive antibody molecules and vectors and hosts comprising said nucleic acid molecules are disclosed. In addition, the present invention provides for compositions, preferably pharmaceutical or diagnostic compositions, comprising the compounds of the invention as well as for specific uses of the antibody molecules, nucleic acid molecules, vectors or hosts of the invention.Type: GrantFiled: February 20, 2003Date of Patent: September 14, 2010Assignees: F. Hoffmann-La Roche AG, Morphosys AGInventors: Michael Bardroff, Bernd Bohrmann, Manfred Brockhaus, Walter Huber, Titus Kretzschmar, Hansruedi Loetscher, Corinna Löhning, Christer Nordstedt, Christine Rothe
-
Publication number: 20100172907Abstract: The present invention relates to antibody molecules capable of specifically recognizing two regions of the ?-A4 peptide, wherein the first region comprises the amino acid sequence AEFRHDSGY as shown in SEQ ID NO: 1 or a fragment thereof and wherein the second region comprises the amino acid sequence VHHQKLVFFAEDVG as shown in SEQ ID NO: 2 or a fragment thereof. Furthermore, nucleic acid molecules encoding the inventive antibody molecules and vectors and hosts comprising said nucleic acid molecules are disclosed. In addition, the present invention provides for compositions, preferably pharmaceutical or diagnostic compositions, comprising the compounds of the invention as well as for specific uses of the antibody molecules, nucleic acid molecules, vectors or hosts of the invention.Type: ApplicationFiled: July 28, 2009Publication date: July 8, 2010Inventors: Michael Bardroff, Bernd Bohrmann, Manfred Brockhaus, Walter Huber, Titus kretzschmar, Hansruedi Loetscher, Corinna Lohning, Christer Nordstedt, Christine Rothe
-
Publication number: 20050169925Abstract: The present invention relates to antibody molecules capable of specifically recognizing two regions of the R-A4 peptide, wherein the first region comprises the amino acid sequence ABFRHDSGY as shown in SEQ ID NO: 1 or a fragment thereof and wherein the second region comprises the amino acid sequence VHHQKLVFFAEDVG as shown in SEQ ID NO: 2 or a fragment thereof. Furthermore, nucleic acid molecules encoding the inventive antibody molecules and vectors and hosts comprising said nucleic acid molecules are disclosed. In addition, the present invention provides for compositions, preferably pharmaceutical or diagnostic compositions, comprising the compounds of the invention as well as for specific uses of the antibody molecules, nucleic acid molecules, vectors or hosts of the invention.Type: ApplicationFiled: February 20, 2003Publication date: August 4, 2005Inventors: Michael Bardroff, Bernd Bohrmann, Manfred Brockhaus, Walter Huber, Titus Kretzschmar, Hansruedi Loetscher, Corinna Lohning, Christer Nordstedt, Christine Rothe